Please assess the completion status of the following clinical trial:

Trial Title: Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Are on stable NA therapy at least 12 months from the screening date (ETV or TDF)~* Has virally suppressed CHB:~HBV DNA \<LLOQ and serum HBsAg \>100 IU/mL~* Has liver imaging to screen for hepatocellular carcinoma or concomitant pancreaticobiliary disease either in the prior 6 months or at screening.~* Is not of childbearing potential or, if of childbearing potential, is not pregnant as confirmed by a negative serum human chorionic gonadotropin test at screening and is not planning a pregnancy during the course of the study.~Main Exclusion Criteria:~* Is an employee of a contract research organization (CRO), vendor, or Sponsor involved with this study.~* Has known hepatocellular carcinoma or pancreaticobiliary disease.~* Neutropenia (defined by two confirmed values within screening period of \<1500/μL).~* Has Gilbert syndrome.~* Shows evidence of worsening liver function, defined as either a confirmed (two assessments at least 3 days apart) increase \>2 ULN ALT or AST or an increase of \>1.5 × first assessed value of TBL or associated with clinical signs or symptoms of liver impairment.~* Has known or suspected non-CHB liver disease~* History of cirrhosis or liver decompensation, including ascites, hepatic encephalopathy, or presence of oesophageal varices.~* Probable or possible F3 stage with a vibration controlled transient elastography (VCTE). Patients with normal baseline ALT and VCTE \>8.8 kPa are excluded. Patients with baseline ALT \>ULN (but \<2ULN per EC5) and who have VCTE \>10.5 kPa at baseline are excluded 11.~* Has known history of alcohol abuse or daily heavy alcohol consumption~* Has clinically relevant immunosuppression, including, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.~* Has used anti-HBV medications other than NAs within 90 days prior to screening.~* Has any of the following exclusionary laboratory results at screening:~  1. Estimated glomerular filtration rate \<60 mL/min/1.73 m2 (the Modification of Diet in Renal Disease formula).~ 2. Thyroid-stimulating hormone \>1.5× ULN or abnormal free triiodothyronine or free thyroxine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)
- Control Arm (Type: PLACEBO_COMPARATOR): Control Arm: Placebo + NA daily (12 patients)

Based on this trial design, predict the completion outcome and termination type (if applicable).